This study is in progress, not accepting new patients
A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Relapsing Forms of Multiple Sclerosis
Summary
- Eligibility
- for people ages 18-65 (full criteria)
- Location
- at Irvine, California and other locations
- Dates
- study startedestimated completion
Description
Summary
Official Title
Keywords
Eligibility
Locations
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- AbbVie
- ID
- NCT03737851
- Phase
- Phase 2
- Study Type
- Interventional
- Last Updated